Screener
Arbutus Biopharma Corporation ABUS Business Segments — Net Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (17) | (28) |
| Foreign exchange (loss) gain | (11) | 4 |
| Total other income | 787 | 1,173 |
| Net income (loss) | $169,695 | $(24,526) |
| Net income (loss) per common share | ||
| Basic | $0.88 | $(0.13) |
| Diluted | $0.87 | $(0.13) |
| Weighted average number of common shares |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's business segments — net income (loss)?
- Arbutus Biopharma Corporation (ABUS) reported business segments — net income (loss) of $169.7M in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — net income (loss) changed year-over-year?
- Arbutus Biopharma Corporation's business segments — net income (loss) increased by 791.9% year-over-year, from -$24.53M to $169.7M.
- What does business segments — net income (loss) mean?
- This is the bottom-line financial result for the specific business segment, calculated by subtracting all segment-related operating expenses from segment revenues. It indicates the profitability or burn rate of the segment's standalone activities.
Ask your AI about Arbutus Biopharma Corporation's business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude